Danielsen W, v der Leyen H, Meyer W, Neumann J, Schmitz W, Scholz H, Starbatty J, Stein B, Döring V, Kalmár P
Abteilung Allgemeine Pharmakologie, Universitäts-Krankenhaus Eppendorf, Universität Hamburg, F.R.G.
J Cardiovasc Pharmacol. 1989 Jul;14(1):171-3. doi: 10.1097/00005344-198907000-00026.
We measured force of contraction and cAMP content in human isolated electrically driven right ventricular trabeculae carneae with and without the addition of isoprenaline (0.2 microM). Basal cAMP content was approximately 200% higher in preparations from nonfailing hearts than from hearts with end-stage myocardial failure. Isoprenaline was less effective in increasing force of contraction in failing (by approximately 100%) than in nonfailing cardiac preparations (by approximately 500%). With isoprenaline, cAMP content was approximately 50% lower in failing than in nonfailing preparations. We conclude that the reduced increase in force of contraction of failing human cardiac preparations with isoprenaline added may be causally related to an inadequately increased cAMP content.
我们在添加和不添加异丙肾上腺素（0.2微摩尔）的情况下，测量了人离体电驱动右心室肉柱的收缩力和环磷酸腺苷（cAMP）含量。与终末期心肌衰竭心脏的标本相比，非衰竭心脏标本中的基础cAMP含量大约高200%。与非衰竭心脏标本（约500%）相比，异丙肾上腺素增加衰竭心脏标本收缩力的效果较差（约100%）。使用异丙肾上腺素时，衰竭标本中的cAMP含量比非衰竭标本低约50%。我们得出结论，添加异丙肾上腺素后，衰竭人体心脏标本收缩力增加减少，可能与cAMP含量增加不足存在因果关系。
